Texas Medical Center
Webster, TX 77598
Harold J. Farber, MD
Texas Children's Hospital
Associate Medical Director, Texas Children's Health Plan
Professor of Pediatrics, Baylor College of Medicine
|Tulane University School of Medicine||fellowship||Pediatric Pulmonary||1997|
|University of Arizona College of Medicine||fellowship||Pediatric Pulmonary||1991|
|Los Angeles County-Univ of Southern Cal||residency||Pediatrics||1990|
|Los Angeles County-Univ of Southern Cal||internship||Pediatrics||1988|
|State University of New York-Stony Brook||medical school||Doctor of Medicine||1987|
Dr. Farber’s diverse clinical interests include asthma, respiratory care of children with muscular dystrophy, respiratory care of technology dependent children, the chronic care of children with complex respiratory diseases, and the treatment of tobacco dependence. Dr. Farber’s research interests focus on clinical, epidemiologic, and health care delivery/quality improvement. Dr. Farber serves as a Co-Investigator for the Baylor College of Medicine site of the American Lung Association Asthma Clinical Research Center (ALA-ACRC) network. Dr. Farber is leading asthma care quality improvement efforts for the Texas Children’s Health Plan.
View News Articles:
|American Academy of Pediatrics||Fellow; Member, Section on Tobacco Control|
|American College of Chest Physicians||Fellow|
|American Thoracic Society||Vice Chair, Tobacco Action Committee|
Farber HJ, Phillips WA, Kocab KL, Hanson DS, Heydemann JA, Dahl BT, Spoede ET, Jefferson LS. Impact of scoliosis surgery on pulmonary function in patients with muscular dystrophies and spinal muscular atrophy. Pediatr Pulmonol 2020 Apr;55(4):1037-1042. doi: 10.1002/ppul.24664. Epub 2020 Feb 3.
Farber HJ, Silveira EA, Vicere DR, Kothari VD, Giardino AP. Oral Corticosteroid Prescribing for Children With Asthma in a Medicaid Managed Care Program. Pediatrics 2017 May;139(5). pii: e20164146.
Farber HJ, Pakhale S, Neptune ER; American Thoracic Society Tobacco Action Committee. Tobacco 21: An Important Public Policy to Protect Our Youth. Ann Am Thorac Soc 2016 Dec;13(12):2115-2118.
Farber HJ, Buckwold FJ, Lachman B, Simpson JS, Buck E, Arun M, Valadez AM, Ruiz T, Alonzo J, Henry A, Cos-Okpalla N, Nguyen K, Brendel W, Small J, Glomb WB. Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants. Pediatrics 2016 Aug;138(2). pii: e20160627.
Farber HJ, Batsell RR, Silveira EA, Calhoun RT, Giardino AP. The Impact of Tobacco Smoke Exposure on Childhood Asthma in a Medicaid Managed Care Plan. Chest 2016 Mar;149(3):721-8.
Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone S, Kovesi T, Kravitz RM, Panitch H, Schramm C, Schroth M, Sharma G, Sievers L, Silvestri JM, Sterni L. Respiratory care of the patient with Duchenne muscular dystrophy: An Official ATS Consensus Statement. American Journal of Respiratory and Critical Care Medicine 2004; 170.:456–465.
Farber, Harold J. Control Your Child's Asthma; A Breakthrough Program for the Treatment and Management of Childhood Asthma (Henry Holt, 2001).
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.